A Study of LY2127399 in Rheumatoid Arthritis

Summary

This study will investigate how LY2127399 works in participants with rheumatoid arthritis (RA) who are not adequately responding to methotrexate. Participants will receive LY2127399 via an injection(s) under the skin at 4 week intervals for up to 52 weeks. Key study procedures include biopsies of the lining of an inflamed joint and blood tests to measure RA activity.

Timeline

Start

2012-05

Primary completion

2013-05

Completion

2013-05

Drugs

Indications